Risk Assessment in the International Food Safety Policy Arena - Can the Multilateral Institutions Encourage Unbiased Outcomes?

In this paper we provide a description of how food safety related scientific evidence is generated and how it is used in the context of risk assessment for international standard-setting at CODEX and in WTO trade disputes. In particular, we discuss the processes leading to policy conclusions on the basis of scientific evidence, with a focus on the interactions involved between private and public sector actors and those between "scientific experts" and others. We identify weaknesses in the current institutional set-up and provide suggestions on how to improve the interaction between different players at the national and international level so as to strengthen the existing system and increase its cost efficiency

One step forward, one step sideways? Expanding research capacity for neglected diseases

<p>Abstract</p> <p>Background</p> <p>There is general agreement, including from the pharmaceutical industry, that current market based methods of generating research into the development of pharmaceutical products that are relevant for developing countries do not work. This conclusion is relevant not just for the most neglected diseases such as leishmaniasis but even for global diseases such as cancer and cardiovascular disease.</p> <p>Discussion</p> <p>Stimulating research will mean overcoming barriers such as patent thickets, poor coordination of research activities, exclusive licensing of new technologies by universities and the structural problems that inhibit conducting appropriate clinical trials in developing countries. In addition, it is necessary to ensure that the priorities for research reflect the needs of developing countries and not just donors. This article will explore each of these issues and then look at three emerging approaches to stimulating research -paying for innovation, priority review sales or vouchers and public-private partnerships, - and evaluate their strengths and weaknesses.</p> <p>Summary</p> <p>All of the stakeholders agree that there is a pressing need for a major expansion in the level of R&D. Whatever that new model turns out to be, it will have to deal with the 5 barriers outlined in this paper. Finally, none of the three proposals considered here for expanding research is free from major limitations.</p

PUBLIC-PRIVATE PARTNERSHIP TO DEVELOP TECHNOLOGY INFRASTRUCTURE: A CASE STUDY OF THE ECONOMIC RETURNS OF DNA DIAGNOSTICS

This paper presents a quantitative case analysis of one US Advanced Technology Program (ATP) public-private partnership that advanced the technology infrastructure of molecular diagnostics, resulting in substantial downstream economic and public health benefits. Biotechnology R&D is generally characterized by technologies requiring substantial investments in time, money, and effort to develop and sustain concepts through long incubation times. Public sponsorship of a partnership between two companies who would have not otherwise collaborated, Affymetrix and Molecular Dynamics, accelerated the development of DNA microarrays and DNA sequencing technologies and induced innovation at competitor firms. Public sponsorship of private-company research accelerated the completion of the Human Genome Project and improved both the quality and rapidity with which the biotechnology industry and medical science acquire genetic information. Counterfactual scenarios were used to quantify net public benefits by estimating the hypothetical costs of achieving the same outcomes as using the processes and technologies the ATP-cofunded innovations superseded.Technology infrastructure, Biotechnology, Case study, Induced innovation,

Managing the Risks Associated with Using Biomedical Ethics Advice

Biomedical ethics, Bioscience industry, Biotechnology, Business ethics, Ethics, Pharmaceutical,

Electrolyte effects on the chiral induction and on its temperature dependence in a chiral nematic lyotropic liquid crystal

Abstract We present a study on the effect of added CsCl and of temperature variation on the chiral induction in a chiral nematic lyotropic liquid crystal (LC) composed of the surfactant cesium perfluorooctanoate (CsPFO), water, and the chiral dopant d-Leucine (d-Leu). The chiral induction was measured as the helical pitch P. The role of the additives CsCl and d-Leu on the phase behavior is investigated and discussed. The thermal stabilization effect of CsCl is shown to lead to an apparent salt effect on the pitch when the pitch is compared at a constant temperature. This apparent effect is removed by comparing the pitch measured for different salt concentrations at a temperature relative to the phase-transition temperatures; thus, the real salt effect on the pitch is described. High salt concentrations are shown to increase the pitch, that is, hinder the chiral induction. The effect is discussed in terms of a decreased solubilization of the amphiphilic chiral solute d-Leu in the micelles due to the salt-induced screening of the surfactant head groups and the consequential denser packing of the surfactants. The temperature variation of the pitch is investigated for all CsCl concentrations and is found to be essentially independent of the salt concentration. The temperature variation is analyzed and discussed in the context of a theoretical model taking into account specific properties of lyotropic liquid crystals. A hyperbolic decrease of the pitch is found with increasing temperature, which is known, from thermotropic liquid crystals, to stem from pretransitional critical fluctuations close to the lamellar phase. However, the experimental data confirmed the theoretical prediction that, at high temperature, that is, far away from the transition into the lamellar phase, the pitch is characterized by a linear temperature dependence which is determined by a combination of steric and dispersion chiral interactions. The parameters of the theoretical expression for the pitch have been determined by fitting the experimental data. The analysis of the salt concentration dependence of these parameters indicates that the chiral induction mechanism of d-Leu is dominated by chiral steric interactions

Collaboration - a competitor's tool: The story of Centocor, an entrepreneurial biotechnology company

Biotechnology companies have relied on alliances for survival and growth since their inception. This history of Centocor illustrates the pivotal role collaborations played for pioneers in the industry. Five years after its founding Centocor had become a competitive and profitable diagnostics company based on partnerships with research institutes and larger health care companies. In 1992, however, Centocor faced collapse, brought on by a departure from collaboration and going it alone in the development and marketing of the company's first therapeutic. What saved the company and enabled it to prosper in therapeutics was a reversion to the old strategy of collaboration.alliances, biotechnology, technology transfer, pharmaceutical, diagnostics,